Community/Retail

Explore the evolving landscape of myelofibrosis treatment, focusing on personalized therapy, JAK inhibitors, and the role of pharmacists in patient care.

Ann Marie Navar, MD, PhD, explains how enlicitide decanoate delivers LDL-C reductions comparable with injectable PCSK9 inhibitors, which could improve access to nonstatin therapy for patients not at goal.

New research reveals weaknesses in the STOPP/START version 3 criteria, highlighting the need for stronger evidence in geriatric medication management.

Technological change and COVID-19–related staffing challenges have intensified the need for pharmacy technician career growth and retention strategies. Mayo Clinic implemented an inclusive 5-tier career ladder with expanded training and compensation, reducing turnover by nearly 50% and improving satisfaction, demonstrating the impact of structured advancement on workforce stability and professional development.

Jordan Harper, DMD, discusses innovative fluoride-free toothpaste tablets with hydroxyapatite, offering effective oral care solutions for all patients.

Insufficient sleep significantly impacts life expectancy, highlighting the need to prioritize quality rest for better health and longevity.

The FDA approves gepotidacin as a groundbreaking oral treatment for uncomplicated urogenital gonorrhea.

A study determined that lifestyle factors and comorbidities were more likely to be associated with the onset of diabetes.

FDA grants Priority Review for gedatolisib, a promising treatment for advanced HR+/HER2- breast cancer, showcasing significant efficacy in recent trials.

Heidi De Souza discusses strategies to enhance RSV vaccine uptake among older adults, emphasizing awareness, coadministration patterns, and public health efforts.

Pharmacists enhance community health by offering test-and-treat services for COVID-19, influenza, strep, and RSV, improving access to care.

Discover how hydroxyapatite toothpaste tablets revolutionize oral care with eco-friendly, effective, and gentle alternatives to traditional fluoride toothpaste.

Discover how ENAMEL revolutionizes oral care with eco-friendly, waterless toothpaste tablets made from clean, natural ingredients.

Improving Health Equity Through Pharmacist-Led Care Is a Collective Necessity Requiring a Multifaceted, Collaborative Approach

Recent research reveals no significant link between prenatal acetaminophen use and increased risks of autism or ADHD in children, challenging FDA claims.

New research reveals PUF60's critical role in triple-negative breast cancer, highlighting RNA splicing as a promising therapeutic target for oncology.

Dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists were found to offer neuroprotective effects to patients who were administered the medications.

Ali Dehghani, DO, highlights that shingles vaccination not only prevents rash but is also associated with lower risks of major cardiovascular events, dementia, and mortality, underscoring pharmacists’ role in patient counseling and preventive care.

The FDA approved oral semaglutide to reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D).

Innovative digital twin technology revolutionizes brain cancer treatment by predicting tumor metabolism and personalizing therapies for better patient outcomes.

High out-of-pocket costs lead patients to skip medications. Financial assistance programs improve adherence, but complex insurance strategies may hinder access.

The glucagon-like peptide-1 (GLP-1) receptor agonist medications evaluated included semaglutide, tirzepatide, and liraglutide.

Nina Masters, PhD, MPH, explains how early adherence to pediatric vaccines strongly predicts timely measles-mumps-rubella (MMR) vaccination.

Food insecurity and social instability significantly increase long COVID risk in children, highlighting the need for targeted public health interventions.

Hawaii has secured a $700 million settlement with the manufacturers of Plavix following a lawsuit alleging they concealed for years the drug's ineffectiveness and potential danger for individuals of East Asian or Pacific Islander descent, a risk that the FDA later required to be disclosed with a boxed warning.

A tour through GLP-1’s unexpected biology.

Polypharmacy poses significant risks for patients, highlighting the need for comprehensive medication reviews and patient involvement.

According to the news release, the manufacturers have 30 days to respond.